20250331-招银国际-讯飞医疗科技-02506.HK-Accelerated_growth_in_2H24_solidifies_leadership_in_medical_AI_5页_1mb

Xunfei Healthcare (2506 HK) Summary

Core Content

Xunfei Healthcare, a leading player in the medical AI sector, reported strong financial performance in 2024, with revenue increasing by 32.0% YoY to RMB734.0mn. The company demonstrated accelerated growth in the second half of the year, with revenue growth rising to 39.6% YoY, signaling robust demand for its medical AI services.

Main Points

• Revenue Growth:

  • 1H24: 17.8% YoY
  • 2H24: 39.6% YoY
  • FY25E: 38.8% YoY
  • FY26E: 36.9% YoY
  • FY27E: 33.0% YoY
  • Expected CAGR of 37.9% from 2024 to 2026E.

• Cost Structure Improvements:

  • SG&A expense ratio declined by 10.3 ppts
  • R&D expense ratio fell by 10.4 ppts
  • Adjusted net loss narrowed by 21.4% YoY to RMB44.8mn

• R&D Investment:

  • Total R&D spending reached RMB296.8mn, or 40.4% of revenue

• Segment Performance:

  • To B & To C businesses saw a significant increase in revenue contribution, rising from 36% in 2023 to 47% in 2024
  • To G segment experienced a 40% YoY growth in 2H24, improving from a 43% decline in 1H24
  • Hospital service revenue increased by 103% YoY to RMB132.0mn
  • Patient service revenue increased by 57% YoY to RMB211.2mn

• Customer Base:

  • Served over 500 secondary and tertiary hospitals
  • Included 40 of China's Top 100 hospitals and 7 of the Top 10

• Technology Advancements:

  • Continued development of large language model (LLM) technologies
  • Accumulated substantial medical domain knowledge and data for reinforcement learning
  • Generated millions of AI-assisted diagnosis suggestions daily
  • Expanded cooperation with leading hospitals for high-quality, anonymized clinical data

Key Financial Metrics

Analyst Recommendation

• Rating: BUY (Maintain)
• Target Price: HK$166.69
• Previous Target Price: HK$170.56
• Up/Downside: 33.3%
• Current Price: HK$125.00

Shareholding and Stock Data

• Market Cap (HK$ mn): 15,109.8
• Total Issued Shares (mn): 120.9

Shareholding Structure

Peer Comparison

Valuation and Profitability

Analyst Certification and Disclosures

• The analyst certifies that the views expressed accurately reflect their personal views and that no part of their compensation is related to the report.
• The analyst confirms no trading in the stock covered in the report within 30 days prior to the report date and no trading for 3 business days after.
• CMBIGM has investment banking relationships with the issuers covered in the report within the preceding 12 months.
• The report is for informational purposes only and does not constitute investment advice.
• The information is based on publicly available data and is not guaranteed for accuracy or completeness.
• CMBIGM may issue other reports with different information or conclusions.
• The report may not be reproduced, reprinted, sold, or published without written consent.

Risk and Disclaimer

• There are risks involved in transacting in any securities.
• Past performance does not indicate future performance.
• Actual events may differ materially from those in the report.
• The value and returns of any investment are uncertain and may fluctuate.
• Investors should independently evaluate investments and consult a professional financial advisor.

Regulatory Information

• The report is distributed solely to major US institutional investors as per Rule 15a-6.
• CMBIGM is not a registered broker-dealer in the United States.
• The report is intended for distribution in the United Kingdom and Singapore to specific categories of investors as defined by local regulations.